Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian Consensus recommendations

Multiple Sclerosis Journal - Experimental, Translational and Clinical

Volumn 1, Issue , 2015, Pages

  Arnold, Douglas L ^a   Li, David ^b   Hohol, Marika ^c   Chakraborty, Santanu ^d   Chankowsky, Jeffrey ^e   Alikhani, Katayoun ^f   Duquette, Pierre ^g   Bhan, Virender ^h   Montanera, Walter ^c   Rabinovitch, Hyman ^d   Morrish, William ^f   Vandorpe, Robert ^h   Guilbert, François ^g   Traboulsee, Anthony ^b   Kremenchutzky, Marcelo ⁱ  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^f Foothills Medical Center   (Canada)

^g CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^h QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

ⁱ LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

magnetic resonance imaging; MRI; Multiple sclerosis; recommendations; treatment response

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; FINGOLIMOD; GADOLINIUM; NATALIZUMAB;

ARTICLE; BRAIN ATROPHY; BRAIN DAMAGE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; EXPANDED DISABILITY STATUS SCALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; INFLAMMATION; META ANALYSIS (TOPIC); MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RHEOENCEPHALOGRAPHY; SCORING SYSTEM; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 85016734718     PISSN: None     EISSN: 20552173     Source Type: Journal    
DOI: 10.1177/2055217315589775     Document Type: Article

References (36)

1. C.H.PolmanS.C.ReingoldB.Banwell. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol2011; 69: 292–302.
2. A.CrimiO.CommowickA.Maarouf. Predictive value of imaging markers at multiple sclerosis disease onset based on gadolinium- and USPIO-enhanced MRI and machine learning. PLoS One2014; 9: e93024.
3. A.PaolilloM.C.PiatellaP.Pantano. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis. A monthly MRI study after triple dose gadolinium-DTPA. J Neurol2004; 251: 432–439.
4. E.FisherR.A.RudickJ.H.Simon. Eight-year follow-up study of brain atrophy in patients with MS. Neurology2002; 59: 1412–1420.
5. L.K.FisnikuP.A.BrexD.R.Altmann. Disability and T2 MRI lesions: A 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain2008; 131(Pt 3): 808–817.
6. L.KapposD.MoeriE.W.Radue. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: A meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet1999; 353: 964–969.
7. Z.CaramanosS.J.FrancisS.Narayanan. Large, nonplateauing relationship between clinical disability and cerebral white matter lesion load in patients with multiple sclerosis. Arch Neurol2012; 69: 89–95.
8. R.A.RudickJ.C.LeeJ.Simon. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol2004; 56: 548–555.
9. L.ProsperiniV.GalloN.Petsas. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol2009; 16: 1202–1209.
10. R.A.BermelX.YouP.Foulds. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β. Ann Neurol2013; 73: 95–103.
11. R.DobsonR.A.RudickB.Turner. Assessing treatment response to interferon-β: Is there a role for MRI?Neurology2014; 82: 248–254.
12. M.P.SormaniJ.RioM.Tintorè. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler2013; 19: 605–612.
13. K.FahrbachR.HuelinA.L.Martin. Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: A systematic literature review and regression analysis. BMC Neurology2013; 13: 180.
14. J.H.SimonR.A.BermelR.A.Rudick. Simple MRI metrics contribute to optimal care of the patient with multiple sclerosis. AJNR Am J Neuroradiol2014; 35: 831–832.
15. J.H.SimonD.LiA.Traboulsee. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers Consensus guidelines. AJNR Am J Neuroradiol2006; 27: 455–461. Revised 2009, http://c.ymcdn.com/sites/www.mscare.org/resource/collection/9C5F19B9-3489-48B0-A54B-623A1ECEE07B/mriprotocol2009.pdf (accessed 27 October 2014).
16. M.FilippiA.RoccaD.L.ArnoldUse of imaging in multiple sclerosis. In: (eds). European handbook of neurological management2011; Vol. 1: 2nd. Oxford, UK: Wiley-Blackwell, pp. 35–51.
17. K.O.LövbladN.AnzaloneA.Dörfler. MR imaging in multiple sclerosis: Review and recommendations for current practice. AJNR Am J Neuroradiol2010; 31: 983–989.
18. M.S.FreedmanD.SelchenD.L.Arnold. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci2013; 40: 307–323.
19. D.L.ArnoldL.Stone. The clinical usefulness of routine MRI assessment. Int MS J2011; 17: 58–62.
20. E.HavrdovaS.GalettaM.Hutchinson. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: A retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing–Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol2009; 8: 254–260.
21. L.KapposE.-W.RadueP.O'Connor. Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis: Results from a phase 3, placebo-controlled study (FREEDOMS). Neurology2011; 76(Suppl 4): PD6.002.
22. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; 380: 1819–1828
23. Kappos L, Radue E-W, Freedman MS, et al. Inclusion of brain volume loss in a revised measure of multiple sclerosis disease-activity freedom: The effect of fingolimod. Presented at the Joint Americas Committee for Treatment and Research in Multiple Sclerosis- European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS), Boston, MA, USA, 10–13 September 2014; abstract FC1.5
24. C.J.BevanB.A.C.Cree. Disease activity free status: A new end point for a new era in multiple sclerosis clinical research?JAMA Neurol2014; 71: 269–270.
25. J.A.CohenF.BarkhofG.Comi. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med2010; 362: 402–415.
26. R.J.FoxD.H.MillerJ.T.Phillips. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med2012; 367: 1087–1097.
27. A.J.ColesC.L.TwymanD.L.Arnold. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet2012; 380: 1829–1839.
28. I.R.LeppertS.NarayananD.Araujo. Interpreting therapeutic effect in multiple sclerosis via MRI contrast enhancing lesions: Now you see them, now you don’t. J Neurol2014; 261: 809–816.
29. A.KutzelniggC.F.LucchinettiC.Stadelmann. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain2005; 128(Pt 11): 2705–2712.
30. C.JacobsenJ.HagemeierK.M.Myhr. Brain atrophy and disability progression in multiple sclerosis patients: A 10-year follow-up study. J Neurol Neurosurg Psychiatry2014; 85: 1109–1115.
31. S.TauhidM.NeemaB.C.Healy. MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis. J Neurol Sci2014; 346: 250–254.
32. J.I.RojasL.PatruccoJ.Miguez. Brain atrophy as a non-response predictor to interferon-beta in relapsing–remitting multiple sclerosis. Neurol Res2014; 36: 615–618.
33. H.VrenkenM.JenkinsonM.A.Horsfield. Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol2013; 260: 2458–2471.
34. P.GiannettiM.PolitisP.Su. Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome. Brain2015; 138(Pt 1): 110–119.
35. J.VersijptJ.C.DebruyneK.J.Van Laere. Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: A correlative study. Mult Scler2005; 11: 127–134.
36. L.HofstetterY.NaegelinL.Filli. Progression in disability and regional grey matter atrophy in relapsing–remitting multiple sclerosis. Mult Scler2014; 20: 202–213.